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Abstract
Background: When vaccinations with vaccinia against smallpox and Bacillus Calmette-
Gue´rin (BCG) against tuberculosis were phased out in some high-income countries
around 1980, the impact on overall mortality was not examined. Recent studies from
low-income countries have suggested that these vaccines are associated with mortality
reductions, not explained by specific disease protection. We examined whether vaccinia
and BCG administered in childhood were associated with long-term mortality reductions
in a high-income population.
Methods: In this case-cohort study, we followed 47 622 schoolchildren from
Copenhagen, Denmark, born 1965 to 1976, from their first health examination to 2010.
This cohort experienced the phase-out of vaccinia and BCG vaccination programmes.
Results: A sub-cohort of 5 316 individuals (699 excluded) was followed for 164 450
person-years (0.2% were lost to follow-up), and 401 deaths due to natural causes (841
deaths in total) occurred in the full cohort. Compared with individuals who had not
received vaccinia or BCG, those who had received both vaccinia and BCG had an ad-
justed hazard ratio (aHR) of 0.54 [95% confidence interval (CI): 0.36–0.81] for mortality
due to natural causes of death; those who only received BCG had an aHR of 0.58 (95% CI:
0.39–0.85). Vaccinia and BCG were not associated with any protection against deaths by
accidents, suicide or murder, the combined aHR being 0.94 (95% CI: 0.62–1.42).
VC The Author 2016. Published by Oxford University Press on behalf of the International Epidemiological Association 1
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Conclusions: Vaccinia and BCG vaccinations were associated with better long-term sur-
vival, which was not explained by specific protection. Vaccines with beneficial non-specific
effects may reduce overall mortality even after the target diseases are eradicated.
Key words: BCG vaccine, heterologous immunity, mortality, non-specific effects of vaccines, smallpox vaccine,
vaccinia
Introduction
The last case of smallpox was diagnosed in 1977 and, in
1980, vaccinia vaccination was stopped globally. In the
same period, several high-income countries phased out the
Bacillus Calmette-Gue´rin vaccine (BCG) against tubercu-
losis since tuberculosis was no longer a major health prob-
lem. No investigations, however, examined whether there
were effects on overall morbidity or mortality levels from
stopping these vaccinations.
Strong indications of non-specific effects (NSE) of vaccines
were discovered in Guinea-Bissau 25 years ago.1 Numerous
studies have now found that live attenuated vaccines includ-
ing vaccinia, BCG, measles and oral polio vaccine (OPV) re-
duce mortality more than expected from specific prevention;
hence, these vaccines have beneficial NSE, presumably
through immune training.2,3 In 2014, the World Health
Organization (WHO) recommended further research on NSE
of vaccines.4 If vaccines have beneficial NSE, it may have
negative public health consequences to stop a vaccination
programme. This possibility requires urgent testing because
the world is about to eradicate polio, measles and rubella.5,6
If eradicated, the live vaccines against these diseases will be
scaled down, stopped or replaced with inactivated vaccines.
Studies of NSE have primarily examined children, but studies
in adults also found that vaccinia and BCG vaccinations were
associated with lower mortality.7–9
In Denmark, individuals born between 1965 and 1976
experienced a phase-out of the compulsory vaccinia vac-
cination given before entering school and of the free of
charge BCG vaccination offered in the first grades of
school (Supplementary Text 1, available as Supplementary
data at IJE online). With information on vaccinia and
BCG vaccination from the frequent school health examin-
ations and with follow-up to the mid life of the individuals
using Danish national registers, we tested whether vaccinia
and BCG vaccinations are associated with lower mortality
due to natural causes of death in Denmark.
Methods
Design, setting and study population
This case-cohort study is based on 47 622 schoolchildren
registered in the Copenhagen School Health Record
Register (CSHRR),10 born 1965–76. This cohort grew up
when vaccinia (compulsory before school entry) and BCG
(recommended at school entry) were phased out
(Supplementary Text 1). This type of study does not re-
quire ethical approval by the Danish Central Scientific
Ethics Committee. Data access permission was granted by
the Danish Protection Agency (ref: 2015–41–3976).
From the CSHRR we selected a 10% random sample of
children within strata of sex and year of birth and also all
children born on the first day of every month. Hence, the
sub-cohort covered 13% of the overall population. The
sub-cohort was to be used in different studies investigating
different health outcomes. When the failure proportion is
<1%, then a sub-cohort of 10% or larger has been shown
to be highly efficient.11 Information on vaccinations,
Key messages
• Studying the cohort of Copenhagen schoolchildren who experienced the phase-out of both BCG and smallpox vaccin-
ations in the 1970s, we found that having received both of these vaccines was associated with a 46% (19–64%) reduc-
tion in the hazard rate for death from natural causes.
• BCG and smallpox vaccinations were not associated with deaths due to non-natural causes (accidents, suicides and
murders).
• Live attenuated vaccines, such as BCG and the smallpox vaccine, may have long-term beneficial non-specific effects
on mortality.
• Caution should be observed before phasing out live attenuated vaccines after eradication of the disease, as is cur-
rently planned for oral polio vaccine and possibly for measles vaccine.
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health and social conditions was computerized from the ori-
ginal records as described and analysed in previous studies
on NSE.12–14 We restricted the analyses to individuals with
a valid personal identification number and full information
on vaccinations and identified confounders (Figure 1).
Exposure and co-variables
Children, regardless of whether they were cases or in the
sub-cohort, were regarded as unvaccinated if this was indi-
cated or alternatively if they lacked information on a par-
ticular vaccine but had information on other early
childhood vaccinations in their health record. We excluded
children with no information of any received childhood
vaccination. Vaccinia and BCG vacccinations were ana-
lysed in four groups (no vaccinia or BCG; vaccinia only;
BCG only; both BCG and vaccinia) and as any of these vac-
cines versus none of them. The available additional variables
were sex, eczema (no information; yes), family social class
based on parental occupation and/or education at school
entry of the child [I (highest); II; III; IV; V; unclassified),
number of siblings (none; 1; 2; 3þ), day-care before school
entry, birth by caesarean section and immigration status.
Outcomes
In 1968, all residents in Denmark and those born there-
after were assigned a personal identification number by
law, which enables linkage of registers. We linked the
CSHRR to the Danish Civil Registration System15 to assess
vital status and to the Danish Register of Causes of
Death16 to assess causes of deaths. Causes of death are
coded according to the WHO’s International Classification
of Diseases (ICD) version 8 (1970–93) and version 10
(from 1994).16
The main outcome was natural deaths, with exclusion
of smallpox and tuberculosis deaths (vaccine-preventable
causes) and congenital malformations, as these could have
affected both vaccination status and mortality
(Supplementary Table 1, available as Supplementary data
at IJE online). We hypothesized that vaccination status
was associated with natural deaths, but not with accidental
deaths, suicides or murders (Supplementary Table 1). The
latter three causes were used as control outcomes to ensure
that there were no general associations between vaccination
status and any cause of death. Alcohol or drug addiction
was often listed as a secondary cause of death. We therefore
conducted an analysis of a possible association between vac-
cination status and deaths related to addiction as an add-
itional control analysis (Supplementary text 2, available as
Supplementary data at IJE online).
Statistical analysis
Adjusted binomial regression was used to calculate risk
ratios for vaccination with vaccinia and BCG, respectively,
according to background factors. Hazard ratios (HRs) for
mortality were estimated using the Cox proportional
Sub-cohort slaudividni5106 All deaths 948 deaths 
Inclusion criteria 
Sub-cohort 
6015 
Natural 
deaths
64 
Accidental 
deaths 
21 
Suicides
6 
Other 
deaths
20 
 Natural 
deaths 
445 
Accidental 
deaths 
213 
Suicides 
120 
Murder 
19 
Undefined 
101 
Congenital 
malformations 
14 
Missing 
cause 
36 
With a valid personal 
identification number 5942  64 21 6 20 445 213 120 19 
101 14 36 
With a located school 
health record 5925  63 20 6 20 442 212 119 19 
100 14 36 
With information of at 
least one childhood 
vaccine 
5551 60 20 6 17 416 199 117 18 
96 12 28 
With information on sex, 
eczema, and family 
social class 
5316 
60 19 6 14  401 188 111 17 89 9 26 
trohoc-esacehtnishtaed148trohoc-busnishtaed99
The Copenhagen School Health Records Register
372 636 individuals born 1930 to 1989 
Background population for this study 
47 622 individuals born 1965 to 1976 
Eligible for the study 
46 239 children with a personal identification number 
Exclusion of 1383 individuals without a personal identification number
Figure 1. Flow chart of the study population. Cause of death categories defined in Supplementary Table 1. The high ratio of accidents to natural
deaths may be because the cohort is only followed up during the first half of their lives.
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hazards model with robust variance estimation to account
for the case-cohort design.17 Age was the time scale and
analyses were stratified by year of birth. Children entered
the study at their first school health examination (earliest
1971). If the date of first school health examination was
missing (53 children in sub-cohort), the child was given the
median entry-age for all children.
Children changed vaccination status on the date of their
registered vaccinations. Children with missing vaccination
dates but confirmed vaccination (262 children in sub-
cohort) entered the study at their last health examination.
Natural deaths not in the sub-cohort were included 1 day
before the individual’s death using Prentice’s method for
case-cohort studies, where cases outside the sub-cohort add
to the numerator but do not add person-time,18 which has
been shown to produce reliable estimates.17 End of follow-
up was death from natural causes or censoring (emigration,
non-natural cause of death, loss-to-follow-up or 25
February 2010), whichever occurred first. The proportional
hazards assumption was investigated by testing if the HR
differed by age (<20/20–30/>30 years). Sex, eczema and
family social class were assumed necessary co-variables to
adjust for confounding using a causal diagram.
We investigated whether sex, eczema, and family social
class were effect modifiers. We also investigated heterogen-
eity of effects by age intervals [<20/20–30/>30 years], age
at vaccination [0–3/3–6/6–9/>9 years), time since vaccin-
ation [0–10/10–20/20–30/>30 years] and birth cohort.
Birth cohorts were divided into 1965–68 (vaccinia and
BCG coverage >80%), 1969–72 (coverage 20–80%) and
1973–76 (coverage <20%). We assessed the HRs for
major disease categories of natural causes of death.
As an alternative way of testing the robustness of our es-
timates, we used stabilized inverse probability of treatment
weighting (IPTW) via exact matching to estimate the aver-
age treatment effect on the treated. We applied method C by
Ma˚nsson et al. for case-cohort studies.19 Another sensitivity
analysis was conducted by restricting the study population
to only children born in the highest family social class, for a
more homogeneous study population. In a third sensitivity
analysis, we analysed the association between vaccination
status and death due to natural causes only within the sub-
cohort, ignoring the cases outside the sub-cohort.
All statistical analyses were conducted using Stata 13.1
(StataCorp LP, College Station, TX). We used R (a language
and environment for statistical computing: R Foundation
for Statistical Computing, Vienna) for data visualization.
Results
The sub-cohort consisted of 5316 children after excluding
699 due to missing health records, exclusion of children
with no childhood vaccinations or missing information on
sex, eczema or family social class (Figure 1). Children with
missing information were less vaccinated with vaccinia and
BCG, more were males, less had eczema and they had a
lower social class (Supplementary Table 2, available as
Supplementary data at IJE online). The sub-cohort was fol-
lowed for 164 450 person-years with a median of 32.1
person-years, and it included 99 deaths (60 being due to
natural causes); 386 (7.3%) emigrated and 11 (0.2%) were
lost to follow-up.
In the background cohort, 948 deaths occurred. Health
records with full information about vaccination and neces-
sary co-variables were obtained for 841 deaths (Figure 1);
401 deaths had natural causes (47.7%), 188 were acci-
dents (22.4%), 111 suicides (13.2%), 17 murders (2.0%),
89 were classified as undefined (10.6%), 26 were missing
(3.1%), and 9 were due to congenital malformations
(Supplementary Table 3, available as Supplementary data
at IJE online) (1.1%). There were no smallpox or tubercu-
losis deaths.
Vaccination coverage decreased in individuals born
from 1965 to 1976 (Supplementary Figure 1, available as
Supplementary data at IJE online). Vaccinia was given at 1
to 8 years of age and was rapidly phased out from 1976 to
1977 (Supplementary Figure 2, available as Supplementary
data at IJE online). BCG was mostly given at school entry
and in the spring (Supplementary Figure 3, available as
Supplementary data at IJE online); few children were BCG
vaccinated in 1978 (Supplementary Figure 3).
Vaccinia coverage was higher among girls than boys
(58.6% versus 55.0%, P-value¼ 0.007) but a difference
was not apparent for BCG (Table 1). Eczema was a contra-
indication for vaccinia, and children with reported eczema
had a lower prevalence of vaccinia and BCG compared with
those without eczema (Table 1). Social class V and unclassi-
fied tended to be less vaccinated compared with social class
I, but the remaining groups showed no obvious trends
(Table 1). The distribution of family social class among the
BCG-vaccinated followed the general change throughout
the discontinuation period (Supplementary Table 4).
The mortality rate was higher among males than fe-
males (aHR ¼ 1.63 (95% CI: 1.32–2.01)), and individuals
with a lower social class tended to have higher mortality
rates. Eczema was not associated with higher mortality
(Supplementary Table 5, available as Supplementary data
at IJE online).
Vaccinia and BCG vaccination and death due to
natural causes
More than 50% of follow-up time came from individuals
who had received both vaccinia and BCG, and this
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combination was associated with lower mortality, the HR
adjusted for year of birth, age, sex, eczema and family so-
cial class (aHR) being 0.54 (95% CI: 0.36–0.81) compared
with individuals who had not received these vaccines
(Table 2). Around 25% of follow-up time came from indi-
viduals who had received only BCG, and they had an aHR
of 0.58 (95% CI: 0.39–0.85) compared with non-vaccinia/
non-BCG-vaccinated individuals. Individuals with vaccinia
only contributed 8% of the follow-up time and had an
aHR of 0.75 (95% CI: 0.47–1.22). Adjusting for all co-
variables, the estimates remained virtually unchanged
(Supplementary Table 6). Consistent with these results, the
alternative analyses using the IPTW approach showed
beneficial effect estimates for both vaccinia and BCG
(Supplementary Table 7, available as Supplementary data
at IJE online). Conducting the analysis only for the sub-
cohort revealed similar estimates for having received both
vaccinia and BCG (Supplementary Table 8, available as
Supplementary data at IJE online). Results were similar
when the analysis was restricted to individuals from the
highest family social class (Supplementary Table 9, avail-
able as Supplementary data at IJE online).
For infectious diseases, cardiovascular diseases, neuro-
logical diseases, major autoimmune diseases and other dis-
eases, the aHR was approximately 0.5 for individuals
having received vaccinia and/or BCG compared with not
having received vaccinia or BCG, and the aHR was ap-
proximately 1 for cancers (Table 3).
Potential effect modification
The effect of vaccinia and/or BCG was the same by sex (P-
value for interaction¼ 0.35) (Table 2). Vaccinia and/or
BCG versus none was associated with lower mortality for
individuals with and without eczema, the beneficial effect
being stronger for individuals with eczema [aHR 0.24
(95% CI: 0.09–0.61)] than individuals without
eczema [aHR 0.64 (95% CI: 0.44–0.93)] (P-value
for interaction¼ 0.05) (Supplementary Table 10,
available as Supplementary data at IJE online). Social
class did not modify the association (Supplementary Table
10).
Individuals who had received both vaccinia and BCG
had similar beneficial effects with increasing age (Table 4).
The age at BCG vaccination was associated with mortality
from natural causes (Supplementary Table 11, available as
Supplementary data at IJE online). Time since vaccination
did not influence the association (Supplementary Table
11). The beneficial effects of vaccinia and BCG may have
been strongest for the birth cohorts 1965–68 and 1973–76
(Table 4), but tests of different effect estimates all gave P-
values over 0.1. When disregarding the last 4 birth years of
the discontinuation period, where potential selection biases
for BCG vaccination would have had the largest effect,
combined vaccinia and BCG vaccination was still associ-
ated with an aHR of 0.59 (CI 95%: 0.36–0.96)
(Supplementary Table 12, available as Supplementary data
Table 1. Distribution of exposure variables and vaccination status at the last school health examination among the sub-cohort
Vaccinia at the last school health examinationa BCG at the last school health examinationa
No Yes RRb Joint chi
square test,
P-value
No Yes RRb Joint chi
square test,
P-value
n¼2298 n¼3018 (95% CI) n¼1227 n¼4089 (95% CI)
Sex
Females 42.4% (1090) 58.6% (1544) 1 (ref) 22.9% (604) 77.1% (2030) 1 (ref)
Males 45.0% (1208) 55.0% (1474) 0.98 (0.96–1.00) 23.2% (623) 76.7% (2059) 0.99 (0.97–1.02)
Eczema
Not reported 42.2% (2113) 57.8% (2889) 1 (ref) 22.5% (1127) 77.5% (3875) 1 (ref)
Yes 58.9% (185) 41.1% (129) 0.89 (0.82–0.96) 31.9% (100) 68.2% (214) 0.92 (0.86–0.99)
Family social class
I 51.4% (196) 48.6% (185) 1 (ref) 0.01 29.4% (112) 70.6% (269) 1 (ref) 0.002
II 46.9% (317) 53.1% (359) 1.01 (0.95–1.07) 20.4% (138) 79.6% (538) 1.04 (0.98–1.11)
III 41.4% (368) 58.6% (520) 1.01 (0.96–1.06) 22.1% (196) 77.9% (692) 1.00 (0.95–1.06)
IV 40.7% (760) 59.3% (1108) 1.02 (0.97–1.07) 21.8% (408) 78.2% (1460) 1.01 (0.96–1.07)
V 40.9% (478) 59.1% (691) 0.98 (0.93–1.03) 24.0% (280) 76.1% (889) 0.97 (0.91–1.02)
Unclassified 53.6% (179) 46.4% (155) 0.91 (0.84–0.99) 27.8% (93) 72.2% (241) 0.94 (0.87–1.01)
aIn this table, the distribution of vaccination status follows the status at the last health examination. In the Cox proportional hazards analyses, individuals are
allowed to change vaccination status (except as in Supplementary Table 7).
bRisk ratios (RR) are calculated with binomial regression and adjusted for other variables in the table as well as birth cohort from 1965–68, 1969–72 and
1973–76.
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at IJE online). The IPTW analysis suggested that the lower
effect in the 1969–72-birth cohort was not due to BCG,
but vaccinia had no beneficial effect in this birth cohort
(Supplementary Table 7).
BCG and vaccinia vaccination and non-natural
and addiction related causes of death
Deaths due to accidents, suicides and murders were not
associated with vaccinia and BCG vaccinations, the com-
bined aHR being 0.94 (95% CI: 0.62–1.42) (Table 5).
Furthermore, vaccinia- and BCG-vaccinated individuals
had the same risk of dying from alcohol or drug-related
causes of deaths as vaccinia- and BCG-unvaccinated indi-
viduals, the aHR being 1.18 (CI 95%: 0.68–2.06)
(Supplementary Text 2, available as Supplementary data at
IJE online). Most undefined deaths were related to alcohol
or drugs and ‘undefined and missing causes of death’ were
therefore not linked to vaccination status, the combined
aHR being 0.91 (CI 95%: 0.42–1.97) (Supplementary
Table 13, available as Supplementary data at IJE online).
Discussion
Vaccinia and BCG combined and BCG independently were
associated with lower mortality due to natural causes com-
pared with not receiving these vaccines. Vaccinia without
BCG showed a similar tendency but this subgroup had lim-
ited follow-up time. Vaccinations were not associated with
deaths due to accidents, suicide, murder or the misuse of
alcohol or drugs.
Strengths and weaknesses
Information about vaccination status was collected system-
atically from standardized vaccination cards at school health
examinations. The personal identification number ensured
virtually complete follow-up to death or emigration.15 The
prospective design precludes any effect of recall bias. A few
BCG-vaccinated children may have been misclassified as
‘not vaccinated’ because late BCG vaccination after school
entry might not have been noted (Supplementary Text 1).
Parents could have forgotten the vaccination cards, resulting
in a misclassification of both vaccinia and BCG status. Such
Table 2. Associations between vaccination status and deaths due to natural causes, overall and by sex
Natural
deathsa n¼401
(60 in sub-cohort)
Sub-cohort
person-years
(164 450)
Sub-cohort
according to latest
vaccine status (n)
Crude age-
adjusted hazard
ratiob (95% CI)
Adjusted hazard
ratioc (95% CI)
Vaccinia and BCG
None 53 (8) 24 414 840 1 (ref) 1 (ref)
Only vaccinia 44 (6) 13 558 387 0.72 (0.45–1.17) 0.75 (0.47–1.22)
Only BCG 65 (15) 40 861 1458 0.58 (0.39–0.85) 0.58 (0.39–0.85)
Both vaccinia and BCG 239 (31) 85 618 2631 0.51 (0.34–0.76) 0.54 (0.36–0.81)
Vaccinia and/or BCG 348 (52) 140 036 4476 0.56 (0.39–0.79) 0.57 (0.40–0.81)
Females, vaccinia and BCG
None 16 (2) 11 797 406 1 (ref) 1 (ref)
Only vaccinia 20 (4) 6877 198 1.03 (0.50–2.12) 1.05 (0.51–2.15)
Only BCG 25 (9) 19 162 684 0.77 (0.40–1.49) 0.79 (0.41–1.52)
Both vaccinia and BCG 89 (14) 43 881 1346 0.60 (0.33–1.09) 0.62 (0.34–1.14)
Vaccinia and/or BCG 134 (27) 69 920 2228 0.68 (0.39–1.20) 0.71 (0.40–1.24)
Males, vaccinia and BCG
None 37 (6) 12 617 434 1 (ref) 1 (ref)
Only vaccinia 24 (2) 6680 189 0.60 (0.33–1.09) 0.61 (0.34–1.11)
Only BCG 40 (6) 21 699 774 0.49 (0.30–0.78) 0.49 (0.30–0.78)
Both vaccinia and BCG 150 (17) 41 738 1285 0.49 (0.30–0.78) 0.50 (0.31–0.80)
Vaccinia and/or BCG 214 (25) 70 116 2248 0.51 (0.34–0.77) 0.52 (0.34–0.78)
Test of interaction between vaccinia and/or BCG versus none and sex, P-value 0.37 0.35
aVaccinia- and BCG-vaccinated individuals were on average born earlier than the non-vaccinated individuals and were therefore older and experienced higher
mortality rates towards the end of follow-up. All hazard ratios adjust for age by stratifying for year of birth.
bStratified by year of birth.
cStratified by year of birth and adjusted for sex, eczema and family social class.
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Table 3. Associations between vaccination status and major disease categories
Vaccinia and/or BCG versus
neither vaccinia nor BCG
Deaths,
unvaccinated
(sub-cohort)
Deaths,
vaccinated
(sub-cohort)
Crude age-adjusted
hazard ratioa
(95% CI),
vaccinia and/or
BCG versus none
Adjusted hazard
ratiob (95% CI),
vaccinia and/or
BCG versus none
All causes of natural deaths 53 (8) 348 (52) 0.56 (0.39–0.79) 0.57 (0.40–0.81)
Cancers 13 (1) 120 (18) 1.02 (0.54–1.92) 1.02 (0.54–1.92)
Cardiovascular diseases 11 (2) 51 (6) 0.36 (0.19–0.70) 0.37 (0.19–0.72)
Infectious diseases 5 (2) 28 (4) 0.46 (0.15–1.42) 0.49 (0.16–1.53)
Neurological diseases 4 (0) 14 (3) 0.22 (0.05–0.92) 0.23 (0.06–0.93)
Major autoimmune diseases 2 (1) 12 (1) 0.30 (0.05–1.64) 0.39 (0.07–1.99)
Other diseases 18 (2) 123 (20) 0.51 (0.27–0.96) 0.53 (0.28–0.98)
aStratified by year of birth.
bStratified by year of birth and adjusted for sex, eczema and family social class.
Cancers: ICD-8 (149.0, 151.9, 153.1, 155.0, 158.0, 160.2, 163.1, 170.3, 170.7, 170.8, 170.9, 171.1, 172.7, 180.0, 186.0, 191.0, 192.5, 202.2, 204.0, 205.0,
205.1, 207.0), ICD-10 (C02.9, C06.9, C11.9, C13.9, C15.9, C16.9, C18.0, C18.6, C18.7, C18.9, C20.9, C22.1, C22.2, C23.9, C25.9, C34.9, C43.8, C43.9,
C49.9, C50.8, C50.9, C51.9, C53.8, C53.9, C55.9, C56.9, C62.9, C70.0, C71.2, C71.9, C74.0, C74.9, C80.9, C81.9, C83.5, C85.1, C85.9, C91.0, C92.0,
C92.1, C92.3, D43.2, D48.9). Cardiovascular diseases: ICD-8 (424.1, 427.2, 428.0, 430.0, 430.9, 433.9, 441.0), ICD-10 (I21.0, I21.3, I21.9, I25.1, I25.9, I26.9,
I31.9, I38.9, I42.0, I42.1, I45.6, I46.0, I46.9, I47.1, I51.7, I60.7, I60.9, I61.0, I61.3, I61.5, I61.9, I62.0, I63.3, I63.9, I64.9, I70.9, I72.9, I82.9). Infectious dis-
eases: ICD-8 (036.1, 066.0, 320.1, 464.0, 481.0) ICD-10 (A36.8, A40.0, A41.2, B19.9, B20.3, B20.6, B20.8, B23.8, B24.9, G00.1, G03.0, I30.1, I80.2, J04.0,
J13.9, J15.0, J18.9, J42.9, K85.9, O86.0). Neurological diseases: ICD-8 (330.3, 330.9, 340.0, 345.9, 347.9), ICD-10 (G35.9, G40.9, G71.0, G93.4, R54.9).
Major autoimmune diseases: ICD-8 (563.0, 734.1), ICD-10 (D82.9, D86.0, E10.0, E10.7, E14.0, E14.1, I05.9, I10.9, M32.9). Other diseases: ICD-8 (079.7,
225.2, 225.3, 227.0, 273.0,,279.0, 303.8, 571.0, 582.0, 631.4), ICD-10 (D32.9, D35.2, D35.3, D61.9, D72.1, E11.9, E27.1, E28.2, E66.9, E84.0, E84.1, E84.8,
E88.0, F10.1, F10.2, F14.1, F19.1, F19.2, F20.0, F20.9, J44.9, J45.9, K70.0, K70.1, K70.3, K70.4, K70.9, K72.9, K74.6, K76.7, K80.8, K86.0, N18.9, N19.9,
O95.9, R98.9, R99.0, R99.9). Of these, 079.7, 149.0, 186.0, 303.8 and 428.0 were not identified as ICD-8 codes. We assumed they were mistakenly entered as
ICD-9 codes.
Table 4. Associations between vaccination status and deaths due to natural causes, stratified by age group and birth cohort
Natural deaths
(sub-cohort)
Adjusted hazard
ratioa (95% CI)
Natural deaths
(sub-cohort)
Adjusted hazard
ratioa (95% CI)
Natural deaths
(sub-cohort)
Adjusted hazard
ratioa (95% CI)
Test for
interaction,
P-value
Up to 20 years old Age 20 to 30 years 30 years and above (max 45 years)
Vaccinia and BCG
None 9 (3) 1 (ref) 25 (3) 1 (ref) 19 (2) 1 (ref)
Only vaccinia 8 (2) 1.73 (0.60–5.04) 7 (2) 0.42 (0.17–1.05) 29 (2) 0.85 (0.43–1.66) 0.13
Only BCG 8 (2) 0.55 (0.22–1.37) 31 (4) 0.42 (0.22–0.79) 36 (9) 0.76 (0.43–1.35) 0.38
Both vaccinia and BCG 25 (5) 0.87 (0.32–2.35) 52 (7) 0.43 (0.22–0.84) 162 (19) 0.59 (0.33–1.08) 0.50
Vaccinia and/or BCG 41 (9) 0.72 (0.33–1.58) 80 (13) 0.42 (0.24–0.74) 227 (30) 0.68 (0.40–1.17) 0.38
1965–68 1969–72 1973–76
Vaccinia and BCG
None 11 (4) 1 (ref) 13 (0) 1 (ref) 29 (4) 1 (ref)
Only vaccinia 32 (3) 0.51 (0.24–1.09) 11 (3) 1.14 (0.50–2.62) 1 (0) 0.48 (0.06–3.61) 0.35
Only BCG 14 (3) 0.56 (0.23–1.32) 34 (9) 0.80 (0.41–1.54) 17 (3) 0.45 (0.24–0.85) 0.47
Both vaccinia and BCG 187 (20) 0.35 (0.18–0.68) 49 (19) 0.97 (0.50–1.87) 3 (1) 0.51 (0.15–1.67) 0.10
Vaccinia and/or BCG 233 (26) 0.38 (0.19–0.74) 94 (22) 0.91 (0.49–1.66) 21 (4) 0.46 (0.25–0.83) 0.12
aStratified by year of birth and adjusted for sex, eczema and family social class.
International Journal of Epidemiology, 2016, Vol. 0, No. 0 7
 at U
niversity Library of Southern D
enm
ark on D
ecem
ber 6, 2016
http://ije.oxfordjournals.org/
D
ow
nloaded from
 
misclassifications would lead to underestimation of any ef-
fect. Eczema was a known contraindication for vaccinia,
but it did not explain why vaccinia and BCG were associ-
ated with a reduced risk of natural death.
The suddenness with which vaccinia was stopped could
have resulted in a vaccinated group including primarily
early vaccinia-vaccinated children. However, the associ-
ation between vaccinia and mortality did not differ by age
of vaccination. Vaccinia vaccinations for the 1969–72
birth cohorts were not associated with any benefit. We
have been unable to identify changes in vaccinia adminis-
tration practices during this period, but it remains possible
that the strain of vaccinia or the vaccination technique
may have varied. Because BCG vaccination, in contrast to
vaccinia vaccination, was gradually phased out, it could be
speculated that the uptake of vaccine was more dependent
on external factors; and, particularly if the more healthy
and privileged children were vaccinated preferentially dur-
ing this period, it could create a spurious beneficial effect
of the BCG vaccine for survival. However, there were no
indications that there was a change in the social compos-
ition during the phase-out years (Supplementary Table 4),
and excluding the last years, where such biases would be
expected to be strongest, did not change the conclusions
(Supplementary Table 12).
The finding that neither vaccinia nor BCG were linked
with the control outcomes or deaths due to alcohol or drug
addiction in adult life, supports that the observed protective
effects of vaccinia and BCG are the result of biology rather
than confounding by parental influence on health related be-
haviours. An alternative explanation is that frail individuals
were less likely to be vaccinated (Supplementary Text 1) and
had a higher risk of dying subsequently (frailty bias20), which
would result in the strengthening of the protective association
between vaccination and death due to natural causes. By
excluding individuals with no information about receiving
any childhood vaccination in their health record, we intended
to exclude very frail children from the reference group. Also
to test for frailty bias, we restricted our analysis to children
born in the highest family social class and, reassuringly, we
observed the same beneficial association of vaccinia and BCG
vaccination and mortality due to natural causes of death
(Supplementary Table 9). Nevertheless, it remains possible
that there were other unknown factors associated with not
receiving vaccination and with natural death that we did not
identify, and the potential impact of vaccinia and BCG on
mortality should be examined in other populations.
Consistency with previous studies
In 1810, when vaccinia vaccination became compulsory in
Copenhagen (coverage above 70%), an extraordinaryT
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reduction in mortality was observed even though registered
smallpox deaths had been low for a decade.21 Already at
that time some physicians reported that vaccinia had
NSE.22 Similarly, BCG was associated with a remarkable
reduction in mortality when first introduced in northern
Sweden in the 1920s.23 Recently, two randomized trials
among low-birthweight-infants showed that BCG given at
birth provided a strong non-specific benefit and that it
reduced neonatal mortality by more than 40% compared
with delayed BCG vaccination.24,25 In a recent observa-
tional study from Spain among children aged less than 15
years, BCG was associated with fewer hospital admissions
for respiratory infections and sepsis.26 Interestingly,
whereas most studies of overall mortality effects of live
vaccines in low-income countries have suggested that fe-
males benefit most from these vaccines, we did not observe
different effect estimates between males and females,
which is in agreement with recent Danish studies of the
beneficial non-specific effects of the live vaccines MMR
and OPV.27,28
Only a few previous studies have evaluated vaccinia
and BCG and mortality among adults.7–9 A prospective 8-
year study of 542 malignant melanoma patients showed
that BCG and vaccinia collectively were associated with an
HR of 0.41 (95% CI: 0.25–0.69) and vaccinia alone was
associated with an HR of 0.55 (95% CI: 0.34–0.89) for
all-cause mortality.9 In our study we found no association
to death due to cancers, but malignant melanoma deaths
were only eight of the 133 cancer deaths in the study. Two
prospective studies conducted in Guinea-Bissau collected
information on vaccinations through reading vaccinia and
BCG scars. With follow-up periods of 4 and 3 years, re-
spectively, both studies found lower mortality among indi-
viduals with vaccinia scars compared with individuals
without any scar, the HRs being 0.60 (95% CI: 0.41–
0.87)7 and 0.22 (95% CI: 0.08–0.61)8 respectively.
Potential mechanisms
Lifelong immunological memory has been shown for vac-
cinia29 and BCG.30 Other studies have found that vaccinia
and BCG may prevent unrelated diseases.9,12–14,31,32 These
NSE may be due to cross-reactivity of T and B memory
cells with other pathogens or due to training of the innate
immune system.33 For example, BCG stimulates monocyte
responses to non-related pathogens, resulting in increased
phagocytosis, reactive oxygen species production, intracel-
lular killing, pattern-recognizing receptor expression and
pro-inflammatory cytokine production.33 These effects can
be long-lasting, possibly due to functional reprogramming
of monocyte precursors in the bone marrow.33
In contrast to intramuscular and hypodermal adminis-
tration, the mode of vaccine administration by skin scarifi-
cation has been shown in animal studies to have important
immune-stimulating properties.34 It is possible that the
particular modes of administrating vaccinia by disruption
of the skin and BCG intradermally contribute to reprog-
ramming of the immune system and the reduced risk of
death, but there are likely other mechanisms involved as
well. The immunological training explaining non-specific
effects of vaccines in childhood is only beginning to be
studied2,33 and there has been virtually no immunological
study of how vaccines may affect the long-term immune
profile.
Conclusion
Vaccinia and BCG administered during childhood were
associated with lower mortality from natural causes during
almost 40 years of follow-up. These observations are con-
sistent with a growing body of evidence documenting that
live attenuated vaccines induce beneficial immune training.
For instance, randomized trials of BCG, measles vaccine
and oral polio vaccine in low-income countries with high
mortality have shown that these vaccines are associated
with beneficial non-specific effects on childhood mortality.
Vaccinia and BCG in Denmark may similarly have long-
term beneficial NSE and reduce adult mortality due to nat-
ural causes of death.
The long-term effects of vaccines have not been tested
in randomized trials, so it cannot be excluded that some of
the beneficial effect in the present study could be due to un-
measured confounding. Still, there are clearly reasons not
only to examine these observations elsewhere but also to
study the possible mechanisms through which vaccinia and
BCG may improve general health. Future studies should
explore how morbidity is affected by these vaccines and
which diseases are most affected. Vaccinia is unlikely to be
reintroduced, but BCG could be used more widely.
Though live attenuated vaccines may cause side effects, if
we understand their non-specific effects, they can be fur-
ther investigated immunologically and in the end it may be
possible to generate these effects in other ways.
Global health programmes aim to eradicate polio and
measles and the corresponding vaccines will be scaled
down, stopped or replaced by inactivated vaccines. Since
BCG and vaccinia may have been associated with long-
term lower mortality, other vaccines should undergo thor-
ough evaluations for potential non-specific health effects
before they are terminated.
Dataset and statistical code can be shared upon request
to the corresponding author but dataset requires approval
by authorities.
International Journal of Epidemiology, 2016, Vol. 0, No. 0 9
 at U
niversity Library of Southern D
enm
ark on D
ecem
ber 6, 2016
http://ije.oxfordjournals.org/
D
ow
nloaded from
 
Supplementary Data
Supplementary data are available at IJE online.
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